Accepted Manuscript

Evaluation of a Risk-guided Strategy for Empiric Carbapenem Use in Febrile Neutropenia

Ai Leng Khoo, Ying Jiao Zhao, Monica Teng, Ding Ying, Jing Jin, Yen Lin Chee, Li Mei Poon, Siew Eng Lim, Liang Piu Koh, Wee Joo Chng, Boon Peng Lim, Li Yang Hsu, Louis Yi Ann Chai

PII: S0924-8579(18)30124-9

DOI: 10.1016/j.ijantimicag.2018.04.017

Reference: ANTAGE 5432

To appear in: International Journal of Antimicrobial Agents

Received date: 23 January 2018
Revised date: 18 April 2018
Accepted date: 29 April 2018



Please cite this article as: Ai Leng Khoo, Ying Jiao Zhao, Monica Teng, Ding Ying, Jing Jin, Yen Lin Chee, Li Mei Poon, Siew Eng Lim, Liang Piu Koh, Wee Joo Chng, Boon Peng Lim, Li Yang Hsu, Louis Yi Ann Chai, Evaluation of a Risk-guided Strategy for Empiric Carbapenem Use in Febrile Neutropenia, *International Journal of Antimicrobial Agents* (2018), doi: 10.1016/j.ijantimicag.2018.04.017

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Highlights

- No significant difference in all-cause mortality was demonstrated between empirical piperacillin-tazobactam and carbapenem therapy.
- However, risk stratified carbapenem use reduced mortality in Gram-negative infections.
- More cases of invasive pulmonary aspergillosis were observed with carbapenem use.



Download English Version:

https://daneshyari.com/en/article/8964071

Download Persian Version:

https://daneshyari.com/article/8964071

<u>Daneshyari.com</u>